Ignite Creation Date:
2024-05-06 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05809752
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2023-03-30
Brief Title:
A First in Human Dose Escalation of Dendritic Cell Vaccine DCV
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A First in Human Dose Escalation of Dendritic Cell Vaccine DCV Administered Intrathecally IT Primed Against HER2HER3 in Patients With Leptomeningeal Disease LMD From Triple-Negative Breast Cancer TNBC or HER2 Breast Cancer HER2BC
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to learn about the effects of the study treatment Dendritic Cell Vaccine DCV to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None